Combination Pharmacotherapy for Cardiovascular Disease
- Combination Pharmacotherapy and Public Health Research Working Group*
-
From the Emory Center for Outcomes Research, Emory University, Atlanta, Georgia; University of California, San Francisco,
San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; and Constella Group, LLC, Durham,
North Carolina.
-
Figure 1. All estimates prepared by Thomas Thom, National Heart, Lung, and Blood Institute. Estimated direct and indirect costs (in billions of dollars) of cardiovascular disease (CVD) and stroke, United States, 2004.
-
Figure 2. The figure is split diagonally in halves, representing opportunity, not current spending, for the spectrum of preventive
and therapeutic care. CHF = congestive heart failure; CVD = cardiovascular disease; DM = diabetes mellitus; HBP = high blood
pressure; MI = myocardial infarction; TC = total cholesterol. Action framework for a comprehensive public health strategy to prevent heart disease and stroke.
Responses to this article
-
Ann Intern Med
October 18, 2005
vol. 143
no. 8
593-599
RSS Feeds
View larger version:Figure 1. All estimates prepared by Thomas Thom, National Heart, Lung, and Blood Institute. Estimated direct and indirect costs (in billions of dollars) of cardiovascular disease (CVD) and stroke, United States, 2004.
View larger version:Figure 2. The figure is split diagonally in halves, representing opportunity, not current spending, for the spectrum of preventive and therapeutic care. CHF = congestive heart failure; CVD = cardiovascular disease; DM = diabetes mellitus; HBP = high blood pressure; MI = myocardial infarction; TC = total cholesterol. Action framework for a comprehensive public health strategy to prevent heart disease and stroke.
